Abel Hall LLC’s Elicio Therapeutics ELTX Stock Holding History

Abel Hall LLC’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.5K	Buy	+10,178	New	+$28.2K	﹤0.01%	877

Other funds holding ELTX

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Moody Lynn & Lieberson Boston, Massachusetts $1.93B AUM 20.85% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Abel Hall LLC's ELTX Position: Q3 2026 in Review

Abel Hall LLC opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 10,178 shares worth $18.5K. The stake represents ﹤0.01% of the portfolio and ranks #877 among its holdings.

13 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

Abel Hall LLC held 10,178 shares of Elicio Therapeutics worth $18.5K as of Q3 2026.
Elicio Therapeutics was a new Abel Hall LLC position in Q3 2026.
Elicio Therapeutics made up ﹤0.01% of Abel Hall LLC's portfolio in Q3 2026, its #877 holding.
13 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.